The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
“Our focus is on ex vivo lentiviral gene therapy of T cells to create CAR Ts and hemopoietic stem cells to address rare genetic diseases, and in particular X-linked severe combined immunodeficiency. So, we have 7 lentiviral gene therapy programs, 6 parties for a mixture of hematologic malignancies, and solid tumors, and our XSCID program.”
Mustang Bio recently announced positive data from the ongoing phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL), presented at the European Hematology Association (EHA) 2021 Virtual Congress.
Investigators saw an overall response rate (ORR) of 93% (n = 14/15) and a complete rate (CR) of 67% (10 of 15) with MB-106 treatment. The ORR was 91% (10 of 11) and CR was 82% (9 of 11) in patients with follicular lymphoma. As of EHA 2021, all patients achieving CR remained in remission. CAR T persistence was seen in all dosages. The treatment had an acceptable safety profile, with cytokine release syndrome (CRS) occurring in 6 patients (40%): 3 cases of grade 1 and 3 cases of grade 2.
GeneTherapyLive spoke with Manuel Litchman, MD, president, chief executive officer, and director, Mustang Bio, to learn more about the company and its pipeline. He discussed the operations of their cell processing facility, trials the company is about to start in X-linked severe combined immunodeficiency, lymphoma and chronic lymphocytic leukemia, and a recently initiated trial in blastic plasmacytoid dendritic cell neoplasm. He also stressed the commitment that Mustang Bio has in treating solid tumors, which is reflected in its pipeline.